Clinical Trials Available
To view a list of available clinical trials, select a type of cancer below. You will get a general overview of the trial, the trial number, and a link to clinicaltrials.gov for the most complete information.
Our collaboration with Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, offers our patients early access to the latest in leading-edge treatments without having to leave the Twin Cities region.
Request Clinical Trial Information
BREAST CANCER:
HR+/HER2-
Adjuvant
22332 / NCT05827081: Adjuvant-WIDER. Phase IIIb study of Ribociclib plus endocrine therapy in high-risk early breast cancer within 3 years of surgery.
Learn more: https://clinicaltrials.gov/study/NCT05827081
1L metastatic
25113 (OPERA-02) / NCT07085767: Phase 3 double blind, active controlled study of Palazestrant with Ribociclib vs Letrozole with Ribociclib for 1st line in ER+, HER2- advanced BC.
Learn more: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2026-02023
2L+ metastatic
USO 25021 / NCT07062965: A phase 3 study of PF-07248144 (KAT6A inhibitor) + Fulvestrant vs SOC in patients with ER+, HER2- MBC who have progressed on prior CDK4/6 inhibitor OR recurred w/in 12 mos of last dose (in adj setting). >/=2 prior lines of tx excluded
Learn more: https://clinicaltrials.gov/study/NCT07062965
23107 / NCT06016738: OPERA-01. Phase 3 study of OP-1250 vs standard of care for ER+, HER2- advanced or MBC following ET & CDK4/6 inhibitor
Learn more: https://clinicaltrials.gov/study/NCT06016738
25042 / NCT06982521: RLY-2608 + Fulvestrant vs. Capivasertib + Fulvestrant for PIK3CA-mutant HR+/HER2- locally advanced or metastatic breast cancer following recurrence or progression with CDK4/6 Inhibitor. Prior PI3K treatment excluded.
Learn more: https://clinicaltrials.gov/study/NCT06982521
HER2+
Adjuvant
21462 / NCT05232916: FLAMINGO 01: Phase 3 study of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2+patients with residual disease or High-Risk PCR after both neoadjuvant and adjuvant trastuzumab-based treatment. Only offered at Maple Grove
Learn more: https://clinicaltrials.gov/study/NCT05232916
TRIPLE-NEGATIVE
Adjuvant
22258 / NCT05633654: ASCENT-05: Phase 3 study of Adjuvant Sacituzumab Govitecan & Pembro vs physician’s choice in TNBC with residual disease after surgery and neoadjuvant therapy. BRCA excluded.
Learn more: https://clinicaltrials.gov/study/NCT05633654
1L locally advanced / Metastatic
24325 / NCT06926868: IZABRIGHT-BREAST01: Phase 2/3 study evaluating Izalonamab brengitecan vs treatment of physician’s choice in patients with previously untreated locally advanced or metastatic triple negative breast cancer OR ER-low HER2 neg MBC ineligible for anti-PD(L)1 therapy.
Learn more: https://clinicaltrials.gov/study/NCT06926868
22320 / NCT06103864: Phase III study of Datopotamab Deruxtecan (Dato-DXd) w/wo Durvalumab vs investigator’s choice in combination with Pembrolizumab in pts with PD-L1 positive locally recurrent inoperable or metastatic triple negative breast cancer
Learn more: https://clinicaltrials.gov/study/NCT06103864
PANCREATIC
2L+ Locally advanced / Metastatic
23292 / NCT04657068: A Phase I/IIa study of ATR Kinase Inhibitor ART0380 with irinotecan in patients with ATM ultra-low metastatic or locally advanced PDAC or acinar cell carcinoma as 2nd line. Prior irinotecan allowed. Okay to screen prior to progression.
Learn more: https://clinicaltrials.gov/study/NCT04657068
GASTRIC
1L Locally advanced / Metastatic
24152 / NCT06764875: Phase 3 study of Rilvegostomig with Fluoropyramidine and T-DXd versus chemo, Trastuzumab, and Pembrolizumab for 1st line in Her2+ locally advanced or metastatic cancer
Learn more: https://clinicaltrials.gov/study/NCT06764875
COLON/RECTAL
Adjuvant
24328 / NCT07023289: Phase 2 study of Telisotuzumab Adizutecan vs standard of care in patients with post adjuvant ctDNA Positive CRC and NED on imaging. MSI-H/dMMR excluded
Learn more: https://clinicaltrials.gov/study/NCT07023289
2L+ Metastatic
24246 / NCT07011576: Phase 2 study of Fruquintinib + FOLFIRI as 2nd line for metastatic CRC. Must have received FOLFOX and Bevacizumab as 1st line.
Learn more: https://clinicaltrials.gov/study/NCT07011576
23292 / NCT04657068: A Phase I/IIa study of ATR Kinase Inhibitor ART0380 with irinotecan in patients with ATM negative metastatic CRC as 3rd line. Must have had 5-FU, oxali, and irinotecan previously. Okay to screen prior to progression.
Learn more: https://clinicaltrials.gov/study/NCT04657068
NON-SMALL CELL LUNG CANCER
Consolidation
25152 (ROSETTA) / NCT07361497: Phase 3 study using pumitamig (PD-L1/ VEGF bispecific antibody) vs durvalumab in unresectable stage III NSCLC without progression after chemoradiation treatment.
Learn more: https://clinicaltrials.gov/study/NCT07361497
1L Unresectable or Metastatic
25156 Accelero / NCT07222566: Phase 3, double-blind, randomized study of PF-08634404 in combination with chemotherapy vs. pembrolizumab in combination with chemotherapy in locally advanced or metastatic NSCLC. Squamous or non-squamous eligible. EGFR, ALK, and ROS1 mutant excluded.
Learn more: https://clinicaltrials.gov/study/NCT07222566
2L+ Metastatic:
25091 / NCT07144280: Phase 3, open-label study of PF-080046054/SGN-PDL1V vs Docetaxel in previously treated PD-L1 positive NSCLC. ALK and EGFR included
Learn more: https://clinicaltrials.gov/study/NCT07144280
24264 / NCT05267626: AU-007: Phase 1/2 study of AUC-007, a monoclonal antibody that binds to IL2 and inhibits IL-2R binding for PDL1+ NSCLC that has progressed on prior PD-L1 therapy
Learn more: https://clinicaltrials.gov/study/NCT05267626
SMALL CELL LUNG CANCER
Limited Stage:
24312 / NCT06773910: BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemo/rad in limited-stage SCLC
Learn more: https://clinicaltrials.gov/study/NCT06773910
1L Extensive Stage
25031 DeLLphi-312 / NCT07005128: Phase 3 open label randomized study of first line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide vs. Durvalumab, carboplatin, Etoposide in untreated ES-SCLC.
Learn more: https://clinicaltrials.gov/study/NCT07005128
2-3L Metastatic:
23243 / NCT06095505: Alisertib PO in patients with extensive stage small cell lung cancer in 2-3 line.
Learn more: https://clinicaltrials.gov/study/NCT06095505
PROSTATE
24310 / NCT05413421: 1L Phase 1/1b study of ORIC-944 alone or in combination with androgen receptor pathway inhibitor in patients with metastatic prostate cancer. Only available at Maple Grove
Learn more: https://clinicaltrials.gov/study/NCT05413421
25044 / NCT07213674: Phase 3 study of Xaluritamig + Abiraterone vs investigators choice in chemo-naïve metastatic CRPC. Xaluritamig is bispecific XmAb T-cell engager targeting STEAP1. Only one prior ARPI allowed,
Prior dz progression or intolerance to Abiraterone excluded.
Learn more: https://clinicaltrials.gov/study/NCT07213674
RENAL CELL CARCINOMA
25176 / NCT07227415: Phase 1b/2 study of Pf-08634404 (PD-1/VEGF bispecific antibody) monotherapy and in combination with other anticancer agents in first line locally advanced or metastatic renal cell carcinoma.
Learn more: https://clinicaltrials.gov/study/NCT07227415
MELANOMA / cSCC
Locally advanced or Metastatic
23335 / NCT06246916: Phase 3 study of Fianlimab & Cemiplimab versus Relatlimab & Nivolumab in unresectable or metastatic melanoma for 1st line treatment
Learn more: https://clinicaltrials.gov/study/NCT06246916
HEMATOLOGY
DLBCL
24205 / NCT06890884: 1st line phase 2 study comparing Zilovertamab Vedotin in combination with R-CHP vs Polatuzumab Vedotin with R-CHP in treatment naïve patients with GCB subtype DLBCL.
Learn more: https://clinicaltrials.gov/study/NCT06890884
MULTIPLE MYELOMA
25138 / NCT07095452: A phase 2/3 randomized study of Etentamig and Daratumumab (Etentamig + D) compared to Daratumumab, Lenalidamide, and Dex (DRD) in newly diagnosed multiple myeloma not eligible for transplant
Learn more: https://clinicaltrials.gov/study/NCT07095452
CERVICAL
21365 / NCT04831580: ROCC: Robotic versus Open Radical Hysterectomy for early stage cervical cancer
Learn more: https://clinicaltrials.gov/study/NCT04831580
22067 Rina-S / NCT05579366: Phase 2 study of Rina-S in recurrent or met SCC, adenosquamous, or adenocarcinoma of the cervix in the 2-3 line setting. Must have received prior platinum based therapy and PD-L1 inhibitor. Part B6
Learn more: https://clinicaltrials.gov/study/NCT05579366
25080 TroFUSE-036 / NCT07216703: A phase 3 open label study using Sacituzumab Tirumotecan in combination with pembrolizumab with or without Bevacizumab compared with SOC as first line maintenance for patients with metastatic cervical cancer. Must have PD-L1 CPS >/=1. Part 2. Must be enrolled prior to induction chemo
Learn more: https://clinicaltrials.gov/study/NCT07216703
ENDOMETRIAL
24306 / NCT06952504: Phase 3 study of Sacituzumab Tirumotecan in combination with pembrolizumab vs pembrolizumab Alone as 1st line maintenance treatment in patients with MMR proficient disease
Learn more: https://clinicaltrials.gov/study/NCT06952504
25109 RAINFOL-03 / NCT07166094: Phase 3 randomized study of Rinatabart Sesutecan (Rina-S) Vs treatment of investigators choice in endometrial cancer after platinum based chemo and PDL-1 therapy. 1-3 prior lines of therapy allowed. Must be eligible to receive Doxorubicin or paclitaxel. Neuroendocrine, carcinosarcoma, and endometrial sarcoma excluded.
Learn more: https://clinicaltrials.gov/study/NCT07166094
24262 BELLA / NCT06906341: Phase 2 study of Relacorilant in combination with Nab-paclitaxel and Bevacizumab in advanced endometrial cancer in 2-3L setting. Endometroid, clear cell, carcinosarcoma, serous or mixed histology included. Pure sarcomas or mucinous cancers excluded. Must have had prior treatment with platinum and PDL1. Neuropathy > Grade 1 exclusionary. Arm C
Learn more: https://clinicaltrials.gov/study/NCT06906341
24303 (BLUESTAR) /NCT07044336 : Phase 3 study of Puxitatug Samrotecan monotherapy vs standard of care in pts with B7-H4-selected advanced/metastatic endometrial cancer who progressed after platinum chemo and PD-L1. 1-2 prior lines allowed. Includes carcinosarcoma. Requires prescreening of tissue.
Learn more: https://clinicaltrials.gov/study/NCT07044336
22067 Rina-S / NCT05579366: Phase 2 study of Rinatabart Sesutecan (Rina-S) in patients with recurrent or progressive metastatic carcinosarcoma in the 2-4L setting. Must have received prior PLT based therapy and PD-L1 inhibitor. Part B5
Learn more: https://clinicaltrials.gov/study/NCT05579366
24100 / NCT06463028: Phase 2 study of Sapanisertib and Serabelisib (PIKTOR) with Paclitaxel for 2nd line or later advanced or recurrent endometrial cancer. PI3K/AKT/mTOR pathway gene alteration required. Optional substudy with insulin suppressing diet.
Learn more: https://clinicaltrials.gov/study/NCT06463028
OVARIAN / PRIMARY PERITONEAL / FALLOPIAN TUBE
Platinum sensitive:
24256 DESTINY / NCT06819007: Phase 3 trial of Enhertu with Bev vs. Bev monotherapy in first-line maintenance therapy in HER2 expressing ovarian cancer. Requires central prescreen. Must have received Bev in front line therapy
Learn more: https://clinicaltrials.gov/study/NCT06819007
22067 / NCT05579366: Phase 2 study of Rinatabart Sesutecan (Rina-S) monotherapy and in combination in patients with platinum sensitive high grade serous/endometrioid ovarian cancer in the 2L. Must have BRCA or HRD positive. Must have rec PARP. Excludes clear cell, mucinous, sarcoma, mixed tumors. Part I
Learn more: https://clinicaltrials.gov/study/NCT05579366
24262 BELLA /NCT06906341: Phase 2 study of Relacorilant in Combination with Nab-paclitaxel and Bevacizumab in advanced high-grade platinum resistant, serous/endometrioid, epithelial ovarian, primary peritoneal, or fallopian-tube cancer as 2-4 line therapy. Mixed serous / endometrioid are permitted. Other mixed histologies excluded.
Learn more: https://clinicaltrials.gov/study/NCT06906341
Platinum Resistant:
24059 REJOICE / NCT06161025: Phase 3 study of Raludotatug Deruxtecan (R-DXd) in high grade serous or endometroid PROC in 2-5 line. R-DXd is a ADC targeting CDH6 with Top1 inhibitor payload. Excludes clear cell, mucinous, sarcoma, mixed, undifferentiated histology
Learn more: https://clinicaltrials.gov/study/NCT06161025
25115 TREVI / NCT07218809: Phase 3 study of AZD5335 vs Mirvetuximab in FRα-high and AZD5335 vs investigator’s choice chemo in FRα-low expressing high grade PROC as 2-4 line. Endometrioid, clear cell, mucinous, sarcoma PLT refract, prior FRα tx or TOP1i ADC excluded.
Learn more: https://www.astrazenecaclinicaltrials.com/study/D8991C00001/
22067 / NCT05579366: Phase 2 study of Rinatabart Sesutecan (Rina-S) in patients with high grade serous, endometroid, or clear cell PROC in 2-4 line setting. Must have positive FRα expression and MIRV naïve. Excludes mucinous, low grade, sarcoma or NE. Part J
Learn more: https://clinicaltrials.gov/study/NCT05579366
25114 MAESTRA 1 / NCT07023627: Phase 2 study of INCB123667 as 2-5L treatment in patients with platinum resistant high grade serous epithelial OC, FP, or PPC with Cyclin E1 overexpression.
Learn more: https://clinicaltrials.gov/study/NCT07023627
24112 CATALINA-2 / NCT06690775: Phase 2 study of TORL-1-23 in advanced platinum resistant epithelial ovarian (including primary peritoneal and fallopian tube cancers) expressing claudin 6 in 2-4 line setting. Tumor must be CLDN6+ positive
Learn more: https://clinicaltrials.gov/study/NCT06690775
21270 / NCT05128825: A Phase 2 study to evaluate efficacy and safety of Azenosertib (ZN-c3) in high grade serous ovarian cancer as 2+line. Must have had prior weekly taxol.
Learn more: https://clinicaltrials.gov/study/NCT05128825
Low Grade
23289 / NCT06072781: Avutometinib plus Defactinib Versus SOC in Patients with recurrent low-grade serous ovarian cancer
Learn more: https://clinicaltrials.gov/study/NCT06072781